Introduction {#s1}
============

Recently, a number of reports have identified genes that are associated with the development of multiple autoimmune diseases suggesting that autoimmune diseases share genetic risk factors.[@R1]--[@R3] For example, *PTPN22* has been associated with the development of type I diabetes mellitus (TIDM), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).[@R4]--[@R6] *STAT4* is a susceptibility gene for the development of SLE and RA.[@R7] [@R8] Together these studies implicate dysregulation of common immune pathways due to polymorphisms in several genes in the development of a variety of autoimmune diseases.

The tumour necrosis factor ligand superfamily member 4 gene (*TNFSF4*, *OX40L*), which encodes for the costimulatory molecule OX40 ligand, has been identified as a susceptibility gene for SLE in multiple studies.[@R9]--[@R11] To date, polymorphisms in *TNFSF4* also have been associated with atherosclerosis,[@R12]--[@R14] but there are no published reports of the association of *TNFSF4* with autoimmune diseases such as RA, TIDM, or systemic sclerosis (scleroderma, SSc).

SSc is a chronic multisystem disease clinically characterised by progressive fibrosis in the skin and internal organs.[@R15] Pathologically, SSc exhibits three cardinal features: inflammation and autoimmunity, vasculopathy and excessive extracellular matrix deposition.[@R15] The immune alterations that lead to the development of SSc are unknown, but multiple lines of evidence suggest that SSc may share common immune alterations with SLE. For example, similar to SLE, patients with SSc have a myriad of circulating antinuclear antibodies.[@R16] Furthermore, peripheral blood cells from a subset of patients with SLE and SSc have a pattern of upregulation of type I interferon associated gene transcripts.[@R17]--[@R19] These data now have been extended at the genetic level where SLE and SSc have been associated with polymorphisms in the interferon regulatory factor 5 (*IRF5*) gene, *STAT4*, *PTPN22* and *FAS*.[@R6]--[@R8] [@R20]--[@R25]

Given the association of polymorphisms in the *TNFSF4* gene region with susceptibility to SLE as well as the potential common alterations in immune function and related genes between SLE and SSc, the current study sought to determine if polymorphisms in the *TNFSF4* gene region are associated with SSc susceptibility in a large case-control study of North American Caucasian patients with SSc and healthy controls.

Methods {#s2}
=======

Patients with SSc and controls {#s3}
------------------------------

A total of 1059 Caucasian patients with SSc and 698 healthy Caucasian controls from the Scleroderma Family Registry and DNA Repository[@R26] and the University of Texas Rheumatology Division,[@R27] dating from 1986 to present, including the Genetics versus Environment in Scleroderma Outcomes Study (GENISOS)[@R16] formed the current cohort. All patients with SSc fulfilled American College of Rheumatology (ACR) preliminary criteria for disease classification[@R28] or had at least three of the five CREST (for 'Calcinosis, Raynaud's phenomenon, Eesophageal dysfunction, Sclerodactyly and Telangiectasias\') features.[@R29] [@R30] Patients were not excluded if they had symptoms of myositis or Sjogren\'s syndrome. Patients in the registry were excluded if they met ACR criteria for SLE. In the division samples, one patient was subsequently diagnosed as having SLE. The patients were classified as limited or diffuse cutaneous SSc according to published criteria.[@R31] All participants provided written informed consent and the study was approved by the Committee for the Protection of Human Subjects of The University of Texas Health Science Centre at Houston.

Autoantibody analysis {#s4}
---------------------

Testing for antinuclear antibodies was performed using indirect immunofluorescence (IIF) and HE*p-*2 cells as antigen substrate (Antibodies Inc, Davis, California, USA). Anti-centromere antibodies (ACA) were determined by their distinctive IIF pattern on HE*p-*2 cells.[@R32] Autoantibodies to topoisomerase I (ATA) were determined by passive immunodiffusion (Inova Diagnostics, San Diego, California, USA). Anti-RNA polymerase III antibodies (ARA) were determined by enzyme-linked immunoassay (MBL, Nagoya, Japan).

SNP selection and genotyping {#s5}
----------------------------

Single nucleotide polymorphisms (SNPs) in the *TNFSF4* gene region were selected based on *TNFSF4* variants identified in two independent candidate gene studies in SLE.[@R9] [@R11] Genomic DNA was extracted from peripheral blood with the PureGene genomic DNA isolation kit (Gentra Systems, Minneapolis, Minnesota, USA). The following *TNFSF4* SNPs were genotyped: rs1234314, rs1234315, rs2205960, rs844644, rs12039904, rs2795288, rs844648, rs844665 and rs10912580, using an ABI TaqMan SNP genotyping assay from Applied Biosystems (Foster City, California, USA). ABI 7900HT real-time thermocycler was used to perform the plate reading. Automated allele calling was performed by allelic discrimination plots using SDS V.2.3 software (Applied Biosystems). Multiple positive (Centre d'Etude du Polymorphisme Humain (CEPH) samples) and negative controls were used in each genotyping assay and allele calls were verified with HapMap data for validation.

Statistical analysis {#s6}
--------------------

Statistical analyses were performed using SAS V.9.1.3 (SAS Institute Inc, Cary, North Carolina, USA) software. Hardy--Weinberg equilibrium (HWE) testing was performed using the exact test for HWE. Allelic and genotypic associations were calculated using the standard Pearson χ^2^ test or Fisher exact test. Statistical significance was considered at p\<0.05 after correcting for multiple comparisons using a false discovery rate method (p~FDR~).[@R33] Logistic regression analysis was performed to confirm these associations. Measures of pairwise linkage disequilibrium (LD) were determined using Haploview (Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA). SAS was used for overall ('omnibus test') haplotype frequency tests as well as for haplotype-specific tests. The 'omnibus test' was evaluated to detect differences in overall haplotype frequency profiles between SSc and controls. Classification and regression tree (CART) analysis was performed to explore interactions between SNPs (CART V.6.0; Salford Systems, San Diego, California, USA) using gender and SNPs of *TNFSF4* as nominal categorical variables to predict the outcome of SSc.[@R34] Logistic regression analysis was performed to verify the SNP interaction observed in CART analysis.

Results {#s7}
=======

Linkage disequilibrium in the TNFSF4 gene region in healthy controls {#s8}
--------------------------------------------------------------------

A candidate gene association study was conducted using 1059 Caucasian patients with SSc and 698 healthy controls. Clinical and serological data for the patients with SSc are presented in [table 1](#T1){ref-type="table"}. Nine *TNFSF4* SNPs previously associated with susceptibility to SLE were genotyped in patients with SSc and controls. All SNPs studied in the *TNFSF4* gene region were in HWE in Caucasian controls (see supplementary material). Pairwise LD was calculated by D′ and r^2^ for *TNFSF4* SNPs typed in Caucasian controls ([figure 1](#F1){ref-type="fig"}). The *TNFSF4* SNPs rs1234314--rs1234315, rs2205960--rs12039904, rs2205960--rs10912580, rs12039904--rs10912580 and rs2795288--rs844648 showed LD in the Caucasian population (r^2^ ≥0.80). Given the tight LD of these SNPs, rs1234315, rs12039904, rs10912580 and rs2795288 were not used in subsequent analyses and the case-control comparisons were performed on the remaining five SNPs tagging the *TNFSF4* region.

###### 

Clinical and serological characteristics of patients with systemic sclerosis

  Characteristic                                                               Value
  ---------------------------------------------------------------------------- ------------------------------------------
  Controls:                                                                    
  Gender                                                                       (N=698)[\*](#T1FN1){ref-type="table-fn"}
   Female                                                                      334 (50.8)
   Male                                                                        323 (49.2)
  Systemic sclerosis:                                                          
  Gender                                                                       (N=1059)
   Female                                                                      935 (88.3)
   Male                                                                        124 (11.7)
  Skin involvement                                                             (N=1004)
   Limited systemic sclerosis                                                  611 (60.9)
   Diffuse systemic sclerosis                                                  393 (39.1)
  SSc-associated autoantibodies                                                (N=1059)
   Anti-centromere                                                             300 (28.3)
   Anti-topoisomerase I                                                        174 (16.4)
   Anti-RNA polymerase III                                                     193 (18.2)
   Neither anti-centromere, anti-topoisomerase I, or anti-RNA polymerase III   392 (37.1)

Values are number (%).

Missing gender information on 41 controls.

![Linkage disequilibrium (LD) and haplotype block structure of the tumour necrosis factor ligand superfamily member 4 gene (*TNFSF4*) within healthy controls. Blocks connecting pairs of single nucleotide polymorphisms (SNPs) are shaded according to the strength of the linkage disequilibrium between the SNPs, from 0.0 (white) to 1.0 (black), as measured by the disequilibrium coefficient D'. As an additional measure of strength of LD, r[@R2] values are given as numerical values within each box.](ard-69-03-0550-fig1){#F1}

*TNFSF4* polymorphisms and association with SSc {#s9}
-----------------------------------------------

Case-control comparisons for genotypes using the χ^2^ test demonstrated significant association for multiple SNPs in the *TNFSF4* gene region ([table 2](#T2){ref-type="table"}). These associations remained significant even after controlling for multiple comparisons using the false discovery rate method. Compared to controls, patients with SSc had a higher frequency of the minor allele at rs1234314 (OR 1.2, 95% CI 1.04 to 1.4), rs2205960 (OR 1.2, 95% CI 1.1 to 1.5) and rs844648 (OR 1.2, 95% CI 1.01 to 1.3). The minor allele frequency at rs844648 was less common in patients with SSc compared to controls (OR 0.8, 95% CI 0.7 to 0.97). These data were confirmed using logistic regression analyses after controlling for gender ([figure 2](#F2){ref-type="fig"}). No significant difference was observed between patients with SSc and controls for the rs844665 variant.

![Estimated risk of the tumour necrosis factor ligand superfamily member 4 gene (*TNFSF4*) single nucleotide polymorphisms (SNPs) in systemic sclerosis (SSc) and subsets of SSc compared to controls by logistic regression controlling for gender.](ard-69-03-0550-fig2){#F2}

###### 

Distribution of the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) SNP genotype in North American Caucasian patients with SSc and normal controls[\*](#T2FN1){ref-type="table-fn"}

                              MAF (%)   Allelic χ^2^ p value and OR                  
  --------------- ----------- --------- ----------------------------- ------ ------- --------------------
  rs1234314 (G)   171444015   41.3      45.8                          0.01   0.019   1.20 (1.04 to 1.4)
  rs2205960 (T)   171458098   21.2      25.0                          0.01   0.019   1.24 (1.1 to 1.5)
  rs844644 (A)    171476118   49.1      44.7                          0.01   0.019   0.84 (0.7 to 0.97)
  rs844648 (A)    171490486   41.4      45.2                          0.03   0.038   1.16 (1.01 to 1.3)
  rs844665 (T)    171515580   7.3       8.3                           0.31   0.31    1.19 (0.9 to 1.5)

Controls are used as reference for all comparisons. bp, base pairs; MAF, minor allele frequency; p~FDR~, corrected p values using Benjamini and Hochberg false discovery rate method; p~U~, uncorrected χ^2^ p values; SSc, systemic sclerosis; SNP, single nucleotide polymorphism.

Analysis of the 5-SNP marker set (rs1234314, rs2205960, rs844644, rs844648, rs844665) in the *TNFSF4* revealed 5 out of 28 specific 5-marker haplotypes that were associated with SSc ([table 3](#T3){ref-type="table"}). Four risk haplotypes were identified: C-G-**A**-**A**-C (p\<10^−4^), **G**-G-C-G-C (p=0.0006), **G**-G-C-G-**T** (p\<10^−4^) and **G**-**T**-C-G-C (p\<10^−4^). Consistent with the individual SNP 3×2 χ^2^ analysis, the C-G-**A**-G-C was found to be protective for the development of SSc (p\<10^−4^). These data support the genetic associations of SNPs in *TNFSF4* with SSc susceptibility observed in the case-control comparisons in [table 2](#T2){ref-type="table"}.

###### 

Haplotype analysis of the 5-SNP marker set in the tumour necrosis factor ligand superfamily member 4 gene (TNFSF4) in Caucasian patients with SSc and controls

  Haplotype[\*](#T3FN1){ref-type="table-fn"}   Controls (N=694)   SSc (N=1050)   χ^2^    p~U~        Effect direction
  -------------------------------------------- ------------------ -------------- ------- ---------- ------------------
  OMNIBUS                                      NA                 NA             164.3   \<0.0001   
  C-G-A-A-C                                    0.6%               4.9%           52.6    \<0.0001          Risk
  C-G-A-G-C                                    43.4%              35.1%          25.3    \<0.0001       Protective
  G-G-C-G-C                                    0.4%               1.7%           12.1    0.0006            Risk
  G-G-C-G-T                                    0.0%               1.4%           20.6    \<0.0001          Risk
  G-T-C-G-C                                    0.6%               3.9%           37.6    \<0.0001          Risk
  Others[†](#T3FN2){ref-type="table-fn"}       55.0%              53.0%                                  Neutral

The order of the SNPs is rs1234314--rs2205960--rs844644--rs844648--rs844665.

Includes 23 other haplotypes.

NA, not applicable; p~U~, uncorrected χ^2^ p values; SSc, systemic sclerosis; SNP, single nucleotide polymorphism.

*TNFSF4* polymorphisms and association with subsets of SSc {#s10}
----------------------------------------------------------

SSc is a clinically heterogeneous disease that is divided into two main clinical subsets based on the extent of cutaneous involvement: limited (lSSc) and diffuse (dSSc).[@R31] Furthermore, the presence of SSc-associated autoantibodies such as ACA, ATA and ARA is associated with distinct clinical subsets characterised by extent of cutaneous involvement and pattern of organ involvement.[@R35] Several studies have recently shown that certain genetic polymorphisms may have stronger associations with particular phenotypic subsets.[@R21] [@R36] Therefore, we compared the frequency of *TNFSF4* SNPs within the clinical and autoantibody subsets of patients with SSc ([table 4](#T4){ref-type="table"}).

###### 

Distribution of the tumour necrosis factor ligand superfamily member 4 gene (*TNFSF4*) SNP alleles in North American Caucasian patients with SSc and normal controls[\*](#T4FN1){ref-type="table-fn"}

                                        Allelic comparison                               
  ----------------------------------- -------------------- ------ ------ ------- ------- --------------------
  rs1234314                                                                              
   Controls                                           1362 58.7   41.3                   
   Patients with systemic sclerosis                   2086 54.2   45.8   0.01    0.019   1.20 (1.04 to 1.4)
   Limited systemic sclerosis                         1202 53.4   46.6   0.009   0.026   1.24 (1.1 to 1.5)
   Diffuse systemic sclerosis                          774 54.3   45.7   0.048   0.048   1.20 (1.1 to 1.4)
   Antibodies                                                                            
   Anti-centromere                                     586 51.7   48.3   0.005   0.018   1.33 (1.1 to 1.6)
   Anti-topoisomerase I                                344 52.0   48.0   0.026   0.052   1.31 (1.02 to 1.7)
   Anti-RNA polymerase III                             380 54.7   45.3   0.17    0.23    1.17 (0.9 to 1.5)
  rs2205960                                                                              
   Controls                                           1378 78.8   21.2                   
   Patients with systemic sclerosis                   2058 75.0   25.0   0.01    0.019   1.24(1.1 to 1.5)
   Limited systemic sclerosis                         1184 74.7   25.3   0.013   0.026   1.26 (1.1 to 1.5)
   Diffuse systemic sclerosis                          764 74.9   25.1   0.037   0.048   1.25 (1.01 to 1.6)
   Antibodies                                                                            
   Anti-centromere                                     586 74.4   25.6   0.032   0.056   1.28 (1.01 to 1.6)
   Anti-topoisomerase I                                342 72.5   27.5   0.012   0.048   1.41 (1.1 to 1.9)
   Anti-RNA polymerase III                             372 74.2   25.8   0.057   0.11    1.29 (0.98 to 1.7)
  rs844644                                                                               
   Controls                                           1378 49.1   50.9                   
   Patients with systemic sclerosis                   2090 44.8   55.2   0.01    0.019   0.84 (0.7 to 0.97)
   Limited systemic sclerosis                         1206 45.1   54.9   0.045   0.06    0.85 (0.7 to 1.0)
   Diffuse systemic sclerosis                          774 43.8   56.2   0.019   0.038   0.81 (0.7 to 0.97)
   Antibodies                                                                            
   Anti-centromere                                     590 44.1   55.9   0.042   0.056   0.82 (0.7 to 1.0)
   Anti-topoisomerase I                                346 43.1   56.9   0.046   0.055   0.79 (0.6 to 1.0)
   Anti-RNA polymerase III                             380 45.8   54.2   0.26    0.26    0.88 (0.7 to 1.1)
  rs844648                                                                               
   Controls                                           1384 41.4   58.6                   
   Patients with systemic sclerosis                   2094 45.1   54.9   0.03    0.032   1.16 (1.01 to 1.3)
   Limited systemic sclerosis                         1206 44.0   56.0   0.18    0.18    1.11 (0.95 to 1.3)
   Diffuse systemic sclerosis                          778 48.2   51.8   0.002   0.008   1.32 (1.1 to 1.6)
   Antibodies                                                                            
   Anti-centromere                                     592 42.6   57.4   0.63    0.63    1.05 (0.9 to 1.3)
   Anti-topoisomerase I                                346 47.1   52.9   0.055   0.055   1.26 (0.99 to 1.6)
   Anti-RNA polymerase III                             382 49.7   50.3   0.004   0.014   1.40 (1.1 to 1.8)

Controls are used as reference for all comparisons.

p~FDR~, corrected p values using Benjamini and Hochberg false discovery rate method; p~U~, raw χ^2^ p values; SSc, systemic sclerosis; SNP, single nucleotide polymorphism.

The minor alleles at *TNFSF4* SNPs rs1234314 and rs2205960 were more common in lSSc compared to controls. No differences were observed with rs844644 and rs844648 between lSSc and controls. Compared to controls, the patients with dSSc had an increased frequency of the minor alleles at *TNFSF4* SNPs rs1234314, rs2205960 and rs844648 and decreased frequency of the minor allele at rs844644. Comparison of patients with and without pulmonary fibrosis or pulmonary hypertension did not reveal any differences in the frequency of the SNPs in the *TNFSF4* gene region.

Using the SSc-associated autoantibodies to subset patients with SSc, a significant association was observed with rs1234214 and ACA-positive (OR 1.3, 95% CI 1.1 to 1.6) and ATA-positive patients with SSc (OR 1.3, 95% CI 1.02 to 1.7) compared to controls. The minor allele at rs2205960 was more frequent in ATA-positive SSc compared to controls (OR 1.4, 95% CI 1.1 to 1.9). Interestingly, only rs844648 was noted to be associated with ARA-positive SSc compared to controls (OR 1.4, 95% CI 1.1 to 1.8). No significant differences were noted in the SSc-associated autoantibody subsets of SSc compared to controls at rs844644.

Additional analyses were performed using logistic regression with gender added to the model ([figure 2](#F2){ref-type="fig"}). The strongest associations were observed with rs2205960, where the minor allele was observed with increased frequency in lSSc and dSSc as well as the autoantibody subsets. The minor allele at rs844644 was protective in all groups except for the patients who were ARA positive. With regards to rs1234314, the associations remained in lSSc, ACA and ATA groups. However, the association of rs1234314 was no longer observed after controlling for gender in the logistic regression analyses. Lastly, with regards to rs844648, logistic regression confirmed the association with dSSc and ARA. Together these data suggest that different polymorphisms in the *TNFSF4* gene region are associated with susceptibility to the distinct autoantibody and skin subsets in SSc.

CART analysis for SNP interaction in the TNFSF4 gene region {#s11}
-----------------------------------------------------------

To identify the SNP(s) in *TNFSF4* that play a more prominent role in SSc susceptibility, CART analysis was performed.[@R37] Accordingly, the five *TNFSF4* polymorphisms and gender were entered as variables in the CART model. CART analysis interactively segregates participants into two subgroups using the most powerful variable classifier for SSc.

[Figure 3](#F3){ref-type="fig"} depicts female gender as the first split. In women, the 'TT/GT' genotype of the *TNFSF4* variant (rs2205960) increased risk for SSc as compared to the 'GG' wild-type genotype (OR = 1.51, 95% CI 1.2 to 1.9) consistent with a dominant model. The individuals with wild-type genotype 'GG' at rs2205960 were subsequently further split by the *TNFSF4* variant (rs855648) into two subgroups: the 'AA' genotype of the *TNFSF4* variant increased risk for SSc as compared to the 'AG/GG' genotypes (OR=2.55, 95% CI 1.3 to 5.3). Therefore, this analysis uncovered a potential interaction between the rs2205960 and rs855648 SNPs in the *TNFSF4* gene region among women patients with SSc. This interaction between the two *TNFSF4* variants, rs2205960 and rs855648, was further tested and confirmed by an interaction model in logistic regression analysis (p=0.0004).

![Cartesian and regression tree analysis (CART) showing an interaction between the tumour necrosis factor ligand superfamily member 4 gene (*TNFSF4*) single nucleotide polymorphisms (SNPs) rs2205960 and rs944648 in systemic sclerosis (SSc). Red test result denotes SSc susceptibility factors.](ard-69-03-0550-fig3){#F3}

Discussion {#s12}
==========

The current report is the first demonstration of an association of polymorphisms in the *TNFSF4* gene region with susceptibility to SSc in North American Caucasians. These associations were similar when comparing lSSc and dSSc with controls. We also identified particular SNPs in the *TNFSF4* gene region that are associated with the SSc-associated autoantibody subsets of SSc. Lastly, the exploratory method of analysis, CART, demonstrated a potential interaction between the *TNFSF4* SNPs rs2205960 and rs855648 among Caucasian women patients with SSc that was confirmed by logistic regression analysis.

TNFSF4 encodes for the protein OX40 ligand (OX40L). OX40L is expressed on dendritic cells, macrophages, B cells, T cells, natural killer (NK) cells as well as non-immune cells such as endothelial cells and smooth muscle cells.[@R38] It is the ligand for the OX40 which is expressed on CD4+ and CD8+ T cells, where it provides a costimulatory signal resulting in T cell proliferation, survival and cytokine production.[@R38] Several studies have suggested that OX40--OX40L interaction may preferentially promote T helper (Th)2 cytokines and may be a negative regulatory signal for interleukin (IL)17 production.[@R39]--[@R41] More recently it has been suggested that OX40--OX40L interactions inhibit the formation of Foxp3+ regulatory T cells.[@R42] In addition to T cell effects, OX40--OX40L interactions also have been reported to be critical in differentiation of B cells and antibody production.[@R43]--[@R45] Lastly, it has been reported that plasmacytoid dendritic cells may regulate T helper responses through a balance of OX40L expression and type I interferon expression such that OX40L alone induces a Th2 response and OX40L with type I interferon may have a Th1 inducing effect.[@R46] Together these studies suggest an important role for OX40--OX40L interactions in critical immunoregulatory checkpoints that are likely involved in the development of autoimmunity. Accordingly, OX40L transgenic mice on the C57/BL6 background develop organ specific inflammation and targeted strategies to block OX40--OX40L interactions have prevented the development of diabetes in the non-obese diabetic mouse and experimental autoimmune encephalomyelitis, a model for multiple sclerosis.[@R47]--[@R49] It is likely that these pathways and OX40L-dependent immune alterations are important in the development of SSc. Indeed serum levels of OX40 have been reported to be elevated in patients with SSc, suggesting that the OX40--OX40L pathway may be involved in SSc.[@R50] However, specifically how the OX40L polymorphisms lead to the development of SSc is unknown.

The current report adds *TNFSF4* to the list of genes that are associated with SSc susceptibility which includes major histocompatibility complex (MHC) class II, *PTPN22*, *AIF1*, *IRF5*, *STAT4* and *FAS*.[@R8] [@R21]--[@R23] [@R36] [@R51] Furthermore, given the association of *TNFSF4* with SLE as well as SSc, it is likely that *TNFSF4* is a gene that confers risk to multiple autoimmune diseases. Why individual patients will develop a specific autoimmune disease such as SLE, RA, or SSc remains unknown. Functional studies of the polymorphisms in these genes as well as studies of gene--gene and gene--environment interactions are necessary to better understand how the genetic associations lead to specific autoimmune diseases.

Our study, despite its large size, is limited to the North American Caucasian population. Current efforts are underway to confirm these findings in other populations. However, we believe that the prior association of *TNFSF4* with SLE and the emerging concepts of shared autoimmune genes provide some validation of our novel findings in SSc. Furthermore, the odds ratios that we observed in the current study are small, but statistically significant. It is well established that SSc and other autoimmune diseases are complex polygenic diseases and it will be important to investigate for interactions among these candidate genes in the future. Another important limitation to consider when interpreting the findings of the current study is that our data demonstrate an association of a region 5′ of the *TNFSF4* gene region with SSc susceptibility. These SNPs have been reported to be within the promoter region of *TNFSF4* but their specific regulatory role is not known.[@R11] Higher resolution genotyping or DNA sequencing of this region gene will help to identify the SNPs involved in SSc pathogenesis and also determine the variation in genetic structure of this gene in various populations.

To summarise, the current report identifies *TNFSF4* as a susceptibility gene for the development of SSc. These data further our understanding of the complex immunopathogenesis of SSc and provide additional support for the emerging concept of shared genes in multiple autoimmune diseases.
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